MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis
Conditions
Leukemia - Multiple Myeloma
Conditions: official terms
Multiple Myeloma
Study Type
Interventional
Study Phase
Phase 2/Phase 3
Study Design
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Intervention
Name: Cyclophosphamide Type: Drug
Name: Mesenchymal stromal cells Type: Biological
Overall Status
Recruiting
Summary
Evaluating the effectiveness of the new protocol which replace the standard immunosuppressive therapy with use of MSCs and CY in patients at high risk of relapse.
Detailed Description
This trial try to find a new way of refractory hematological malignancies treatment. Aim of this study evaluating the effectiveness of the new protocol which replace the standard immunosuppressive therapy with use of MSCs and CY in patients at high risk of relapse.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 65 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Refractory forms of acute leukemia, but in complete remission (CR)

- Second and third remission of acute leukemia

- 2nd and 3rd chronic phase chronic myelogenous leukemia (CML) (or Ph + ALL)

- relapsed multiple myeloma

- advanced leukemia

Exclusion Criteria:

- ICU

- Mechanical ventilation
Location
BMT department
Moscow, Russian Federation
Status: Recruiting
Contact: Elena Parovichnikova, Prof MD PhD - +79161487131 - kuzlara@rambler.ru
Start Date
January 2014
Completion Date
January 2016
Sponsors
National Research Center for Hematology, Russia
Source
National Research Center for Hematology, Russia
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page